Security
Telix Pharmaceuticals Limited American Depositary Shares · TLX
TLXNASDAQotherCurrentCIK 2007191Updated Oct 30, 2026
TLX price & chart
Loading TradingView…
NASDAQ:TLX on TradingView ↗In the news
Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman News provided by Hagens Berman Sobol Shapiro LLP Jan 08, 2026, 13:00 ET Share this article Share to X Share this article Share to X Part ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Profit or LossUSD | -7,125,000Source | 49,919,000Source | 5,211,000Source |
| Additional Financial Items | |||
| AdjustmentsForCurrentTaxOfPriorPeriodAUD | — | 0Source | 0Source |
| AdjustmentsForDeferredTaxOfPriorPeriodsAUD | — | 0Source | 0Source |
| AdjustmentsForSharebasedPaymentsUSD | 19,350,000Source | 19,660,000Source | 8,786,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | -1,926,000Source | -17,317,000Source | 2,124,000Source |
| GeneralAndAdministrativeExpenseUSD | 95,789,000Source | 129,830,000Source | 74,181,000Source |
| GoodwillUSD | 198,988,000Source | — | — |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesUSD | 21,298,000Source | 2,809,000Source | 10,253,000Source |
| InterestPaidClassifiedAsOperatingActivitiesUSD | 13,700,000Source | 4,730,000Source | 785,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesUSD | 5,843,000Source | 10,856,000Source | 1,629,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 5,237,000Source | 2,015,000Source | 2,222,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | 529,000Source | 655,938,000Source | 5,756,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | 18,084,000Source | 19,710,000Source | 1,115,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | 819,000Source | 1,115,000Source | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cost of Goods and Services Sold | —Source | —Source | —Source |
| Total RevenueUSD | 803,794,000Source | 783,207,000Source | 502,547,000Source |
| Additional Financial Items | |||
| ApplicableTaxRatenumber | 0.3Source | — | — |
| AverageEffectiveTaxRatenumber | — | 0.3Source | 0.3Source |
| BasicEarningsLossPerShareUSD per share | -0.02Source | 15.07Source | 1.63Source |
| CurrentTaxExpenseIncomeUSD | 13,994,000Source | 32,422,000Source | 14,357,000Source |
| DeferredTaxExpenseIncomeUSD | -12,135,000Source | -26,285,000Source | -16,481,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossUSD | 18,590,000Source | 32,128,000Source | 15,163,000Source |
| DepreciationAndAmortisationExpenseUSD | 21,506,000Source | 8,018,000Source | 6,743,000Source |
| DepreciationRightofuseAssetsUSD | 7,776,000Source | 2,332,000Source | 1,457,000Source |
| DilutedEarningsLossPerShareUSD per share | -0.02Source | 14.46Source | 1.61Source |
| EmployeeBenefitsExpenseUSD | 219,528,000Source | 173,510,000Source | 109,849,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | 19,146,000Source | 19,660,000Source | 8,786,000Source |
| FinanceCostsUSD | 40,868,000Source | 36,936,000Source | 13,772,000Source |
| FinanceIncomeUSD | 5,826,000Source | 10,862,000Source | 1,019,000Source |
| GeneralAndAdministrativeExpenseUSD | 95,789,000Source | 129,830,000Source | 74,181,000Source |
| GrossProfitUSD | 426,438,000Source | 509,678,000Source | 314,390,000Source |
| ImpairmentLossRecognisedInProfitOrLossGoodwillUSD | 0Source | 0Source | — |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD | -566,000Source | — | -804,000Source |
| IncomeTaxExpenseContinuingOperationsUSD | 1,859,000Source | 6,137,000Source | -2,124,000Source |
| InterestExpenseUSD | 181,000Source | 82,000Source | 148,000Source |
| InterestExpenseOnLeaseLiabilitiesUSD | 3,637,000Source | 745,000Source | 636,000Source |
| OtherIncomeAUD | — | 442,000Source | 21,000Source |
| ProfessionalFeesExpenseUSD | 16,541,000Source | 17,508,000Source | 12,644,000Source |
| ProfitLossAttributableToOwnersOfParentUSD | -7,125,000Source | 49,919,000Source | 5,211,000Source |
| ProfitLossBeforeTaxUSD | -5,266,000Source | 56,056,000Source | 3,087,000Source |
| ProfitLossFromOperatingActivitiesUSD | 29,776,000Source | 82,130,000Source | 15,840,000Source |
| ResearchAndDevelopmentExpenseUSD | 171,249,000Source | 194,637,000Source | 128,537,000Source |
Offerings
Registration 333-293611
Filing attachments
ef20070388_ex99-1.htm · 6-K · 2026-04-14
Exhibit 99.1 Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia ASX ANNOUNCEMENT Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia ASX ANNOUNCEMENT Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds Melbourne (Australia) and Indianapolis, IN (U.S.) - April 14, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) (“ Te…
Read attachment ↗ef20070387_ex99-1.htm · 6-K · 2026-04-14
Exhibit 99.1 Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia ASX ANNOUNCEMENT Telix Refinances Convertible Bonds Melbourne (Australia) and Indianapolis, IN (U.S.) - April 14, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) (“Telix”) today launches an offering of US$550 million convertible notes due 2031 to be issued by its wholly-owned subsidiary, Telix Pharmaceuticals (Investments) Inc. (the “Issuer”), and gu…
Read attachment ↗ef20070387_ex99-2.htm · 6-K · 2026-04-14
Exhibit 99.2 Post- treatment Pre- treatment Investor presentation April 14, 2026 ASX: TLX | NASDAQ: TLX 18F-FET scan published in EJNMMI showing a patient with recurrent glioblastoma (GBM) who experienced a near-complete response following treatment with TLX101-Tx (Iodofalan (¹³¹I), Telix's investigational LAT1-targeted therapy. Patient representative scans, individual results may vary. You should read this presentation together with our risk factors, as disclosed in our most recently filed re…
Read attachment ↗telix-ex419xformofdeedofin.htm · 20-F · 2026-02-20
Exhibit 4.19 Deed of Indemnity and Insurance Telix Pharmaceuticals Limited ACN 616 620 369 and insert Officer name Page | 2 TEL005_1700042_030. DOC Table of Contents Table of Contents Table of Contents to update table of contents - press F9 1Definitions and Interpretation3 1.1Definitions3 1.2Interpretation5 2Indemnity6 2.1General indemnity6 2.2Continuing indemnity7 2.3Additional indemnity7 3Conduct and obligations7 3.1Notification7 3.2Advancement or payment of costs7 3.…
Read attachment ↗telix-ex43xformofdeedofind.htm · 20-F · 2026-02-20
Exhibit 4.3 Deed of Indemnity, Access and Insurance Telix Pharmaceuticals Limited ACN 616 620 369 and INSERT FULL NAME OF DIRECTOR Page | 2 Table of Contents Table of Contents Table of Contents to update table of contents - press F9 1Definitions and Interpretation3 1.1Definitions3 1.2Interpretation6 2Indemnity7 2.1General indemnity7 2.2Continuing indemnity7 2.3Additional indemnity8 3Conduct and obligations8 3.1Notification8 3.2Advancement or payment of costs8 3.3Proceedi…
Read attachment ↗